메뉴 건너뛰기
Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy: Third Edition
Volumn , Issue , 2012, Pages 164-198
Drug toxicity
Author keywords

[No Author keywords available]
Indexed keywords

EID: 84923630812     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter
Times cited : (1)
References (10)
  • 1
    • 0036782116 scopus 로고    scopus 로고
    • Putting chirality to work: the strategy of chiral switches
    • An overview of enantiomericspecific properties of drugs and the strategies of switching drugs from achiral to chiral preparations.
    • Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 2002;1:753-768. (An overview of enantiomericspecific properties of drugs and the strategies of switching drugs from achiral to chiral preparations.)
    • (2002) Nat Rev Drug Discov , vol.1 , pp. 753-768
    • Agranat, I.1    Caner, H.2    Caldwell, J.3
  • 2
    • 12144273878 scopus 로고    scopus 로고
    • Genetic aspects of immune-mediated adverse drug effects
    • Overview of immune-mediated adverse effects, including detailed mechanistic information.
    • Bugelski PJ. Genetic aspects of immune-mediated adverse drug effects. Nat Rev Drug Discov 2005;4:59-69. (Overview of immune-mediated adverse effects, including detailed mechanistic information.)
    • (2005) Nat Rev Drug Discov , vol.4 , pp. 59-69
    • Bugelski, P.J.1
  • 3
    • 33744966030 scopus 로고    scopus 로고
    • Major congenital malformations after first-trimester exposure to ACE inhibitors
    • Report of teratogenic effects of ACE inhibitors.
    • Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-2451. (Report of teratogenic effects of ACE inhibitors.)
    • (2006) N Engl J Med , vol.354 , pp. 2443-2451
    • Cooper, W.O.1    Hernandez-Diaz, S.2    Arbogast, P.G.3
  • 4
    • 63249123940 scopus 로고    scopus 로고
    • Current strategies in the development of anti-obesity drugs and their safety concerns
    • Provides examples of drug development guided by knowledge of mechanisms of toxicity.
    • Elangbam CS. Current strategies in the development of anti-obesity drugs and their safety concerns. Vet Pathol 2009;46:10-24. (Provides examples of drug development guided by knowledge of mechanisms of toxicity.)
    • (2009) Vet Pathol , vol.46 , pp. 10-24
    • Elangbam, C.S.1
  • 5
    • 67049169349 scopus 로고    scopus 로고
    • Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen
    • Demonstrates use of genetically engineered animals to study mechanisms of toxicity.
    • Fujimoto K, Kumagai K, Ito K, Arakawa S, Ando Y, Oda S, Yamamoto T, Manabe A. Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen. Toxicol Pathol 2009;37:193-200. (Demonstrates use of genetically engineered animals to study mechanisms of toxicity.)
    • (2009) Toxicol Pathol , vol.37 , pp. 193-200
    • Fujimoto, K.1    Kumagai, K.2    Ito, K.3    Arakawa, S.4    Ando, Y.5    Oda, S.6    Yamamoto, T.7    Manabe, A.8
  • 6
    • 0034605712 scopus 로고    scopus 로고
    • Idiosyncratic drug reactions
    • Reviews mechanisms of idiosyncratic reactions, with focus on toxic metabolites.
    • Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions. Lancet 2000;356:1587-1591. (Reviews mechanisms of idiosyncratic reactions, with focus on toxic metabolites.)
    • (2000) Lancet , vol.356 , pp. 1587-1591
    • Knowles, S.R.1    Uetrecht, J.2    Shear, N.H.3
  • 7
    • 19744374994 scopus 로고    scopus 로고
    • Combinatorial biomarkers: from early toxicology assays to patient population profiling
    • Use of biomarkers for preclinical and early clinical testing.
    • Koop R. Combinatorial biomarkers: from early toxicology assays to patient population profiling. Drug Discov Today 2005;10:781-788. (Use of biomarkers for preclinical and early clinical testing.)
    • (2005) Drug Discov Today , vol.10 , pp. 781-788
    • Koop, R.1
  • 8
    • 18944401259 scopus 로고    scopus 로고
    • Elucidating mechanisms of drug-induced toxicity
    • Introduces the concept of a mechanismbased approach to drug toxicity.
    • Liebler DC, Guengerich FP. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 2005;4:410-420. (Introduces the concept of a mechanismbased approach to drug toxicity.)
    • (2005) Nat Rev Drug Discov , vol.4 , pp. 410-420
    • Liebler, D.C.1    Guengerich, F.P.2
  • 9
    • 32644469104 scopus 로고    scopus 로고
    • Drug-related hepatotoxicity
    • Overview of pharmacogenomic approaches to understanding and predicting drug hepatotoxicity.
    • Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-739. (Overview of pharmacogenomic approaches to understanding and predicting drug hepatotoxicity.)
    • (2006) N Engl J Med , vol.354 , pp. 731-739
    • Navarro, V.J.1    Senior, J.R.2
  • 10
    • 18044392731 scopus 로고    scopus 로고
    • Drug-induced myopathies: an overview of the possible mechanisms
    • Overview of mechanisms leading to skeletal muscle toxicity.
    • Owczarek J, Jasińska M, Orszulak-Michalak D. Drug-induced myopathies: an overview of the possible mechanisms. Pharmacol Rep 2005;57:23-34. (Overview of mechanisms leading to skeletal muscle toxicity.)
    • (2005) Pharmacol Rep , vol.57 , pp. 23-34
    • Owczarek, J.1    Jasińska, M.2    Orszulak-Michalak, D.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.